Prior to treatment with ribociclib, patients’ tumor analyzations monitored cyclin D1/D3 amplification, CDK4/CDK6 amplification, CDK4/CDK6 mutations, and p16 mutations. This evidence concerns the gene CDK4 and neoplasm.